A comparison between inhaled salmeterol and theophylline in the short-term treatment of stable chronic obstructive pulmonary disease

Pulmonary Pharmacology and Therapeutics

Volumn 18, Issue 2, 2005, Pages 103-108

  Broseghini, Cristina ^a   Testi, Renato ^b   Polese, Guido ^c   Tosatto, Roberta ^b   Rossi, Andrea ^c  

^a MAGGIORE HOSPITAL   (Italy)

^b GSK   (Italy)

^c OSPEDALI RIUNITI   (Italy)

Author keywords

Chronic obstructive pulmonary disease (COPD); Efficacy; Safety; Salmeterol; Spirometry; Theophylline

Indexed keywords

PREDNISONE; SALMETEROL; THEOPHYLLINE;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HUMAN; LUNG FUNCTION; MALE; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SIDE EFFECT; SLOW DRUG RELEASE; TITRIMETRY;

ADMINISTRATION, INHALATION; AGED; ALBUTEROL; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE; PREDNISONE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; THEOPHYLLINE; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 11844280320     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pupt.2004.10.006     Document Type: Article

References (21)

1. R.A. Pauwels, S. Buist, and P. Calverley Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease Am J Respir Crit Care Med 163 2001 1256 1276
2. M. Cazzola, G. Di Lorenzo, and F. Di Perna Additive effects of salmeterol and fluticasone or theophylline in COPD Chest 118 2000 1576 1581
3. R. ZuWallack, D.A. Mahler, and D. Reilly Salmeterol plus theophylline combination therapy in the treatment of COPD Chest 119 2001 1661 1670
4. A. Rossi, P. Kristufek, and B.E. Levine Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral slow-release theophylline in the treatment of COPD Chest 121 2002 1058 1069
5. J.F. Donohue The expanding role of long-acting β2-agonists Chest 118 2000 283 285
6. B. Jarvis, and A. Markham Inhaled salmeterol Drugs Aging 18 2001 1 29
7. P. Thomas, J.A. Pugsley, and J.H. Stewart Theophylline and salbutamol improve pulmonary function in patients with irreversible chronic obstructive pulmonary disease Chest 101 1992 160 165
8. American Thoracic Society Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 152 1995 S72 S120
9. Standardization of Spirometry 1994 Update The official statement of the American Thoracic Society Am J Respir Crit Care Med 152 1995 1107 1136
10. D. Murciano, M.H. Auclair, and R. Pariente A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease N Engl J Med 320 1989 1521 1525
11. P.W. Jones, and T.K. Bosh Quality of life changes in COPD patients treated with salmeterol Am J Respir Crit Care Med 155 1997 1283 1289
12. B.L.P. Maesen, C.J.J. Westermann, and V.A.M. Duurkens Effects of formoterol in apparently poorly reversible chronic obstructive pulmonary disease Eur Respir J 13 1999 1103 1108
13. D.E. O'Donnel, L. Forkert, and K.A. Webb Evaluation of bronchodilator responses in patients with irreversible emphysema Eur Respir J 18 2001 914 920
14. L. Dal Vecchio, G. Polese, and R. Poggi Intrinsic positive end-expiratory pressure in stable patients with chronic obstructive pulmonary disease Eur Respir J 3 1990 74 80
15. U.S. Hatipoglu, F. Laghi, and M.J. Tobin Does inhaled albuterol improve diaphragmatic contractility in patients with chronic obstructive pulmonary disease? Am J Respir Crit Care Med 160 1999 1916 1921
16. I. Cerveri, R. Pellegrino, and R. Dore Mechanisms for isolated volume response to a bronchodilator in patients with COPD J Appl Physiol 88 2000 1989 1995
17. P.L. Paggiaro, D. Giannini, and A. Di Franco Comparison of inhaled salmeterol and individually dose-titrated slow release theophylline in patients with reversible airway obstruction. European Study Group Eur Respir J 9 1996 1689 1695
18. S. Nutini, T. Martini, and R. Righi Long-term treatment of asthmatic patients with salmeterol vs slow-release theophylline Respir Med 92 1998 683 690
19. M. Taccola, L. Bancalari, and G. Ghignoni Salmeterol versus slow-release theophylline in patients with reversible obstructive pulmonary disease Monaldi Arch Chest Dis 54 1999 302 306
20. G. Di Lorenzo, G. Morici, and A. Drago Tolerability and effects on quality of life of inhaled salmeterol 50 g b.i.d. and oral twice daily dose-titrated theophylline in a patient population with mild to moderate chronic obstructive pulmonary disease. Italian Study Group Clin Ther 20 1998 1130 1148
21. M. Cazzola, F. Imperatore, and A. Salzillo Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhytmias and hypoxemia Chest 114 1998 411 415